Background: Diagnostic interpretations of melanocytic skin lesions vary widely among pathologists, yet the underlying reasons remain unclear.
Conclusion: Diagnoses are more accurate among pathologists with specialty training and those with more experience interpreting melanocytic lesions. These findings support the practice of referring difficult cases to more experienced pathologists to improve diagnostic accuracy, although the impact of these referrals on patient outcomes requires additional research. ( J Am Acad Dermatol 2018;79:52-9.)
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The accuracy and reproducibility of diagnostic interpretations of melanocytic skin lesions vary widely among pathologists in some portions of the histologic disease spectrum, yet the underlying reasons for this remain unclear. 1 This study aimed to identify pathologist characteristics associated with this variability. Previous studies have identified considerable diagnostic variation; however, these have in general involved small series of selected cases and for the most part have been conducted among specialists in academic rather than community settings. [2] [3] [4] [5] [6] [7] These studies have not addressed differences among pathologists with varying degrees of training and experience, and few have categorized lesions according to characteristics that might be associated with diagnostic difficulty. We hypothesized that greater experience and higher levels of formal training would be associated with increased diagnostic accuracy and reproducibility.
METHODS

Human subjects
Detailed information about the study design and data collection is provided elsewhere. [8] [9] [10] [11] [12] This study was approved by the institutional review boards of the University of Washington, Fred Hutchinson Cancer Research Center, Oregon Health and Science University, Rhode Island Hospital, and Dartmouth College. Participating pathologists provided informed consent.
Participants
Pathologists who had completed their residency and/or fellowship training, had interpreted cutaneous melanocytic lesions in their own clinical practices within the previous year, and were expected to interpret such lesions for the following 2 years were eligible to participate.
Skin biopsy cases
The 240 test cases were selected from routine cases that included shave, punch, and excisional skin biopsies of melanocytic lesions. A new hematoxylin-eosinestained glass slide was prepared for each case. Three experienced dermatopathologists independently reviewed each case, after which an in-person consensus review using a modified Delphi approach 13 was conducted to achieve a consensus reference diagnosis. Each case was assigned to 1 of the 5 classes by using the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx) classification tool, which incorporates treatment recommendations. 11 It was assumed that the specimen margin was positive for the purpose of management recommendations. Examples of potential diagnostic terms for each MPATH-Dx class, along with associated treatment recommendations, are as follows: (I) nevus/mild atypia (no further treatment required), (II) moderate atypia/dysplasia (consider narrow but complete excision margin \5mm), (III) severe dysplasia/melanoma in situ (excision with 5-mm margins), (IV) pT1a invasive melanoma (wide excision with $1-cm margin), and (V) pT1b or higher invasive melanoma (wide excision with $1-cm margin with possible additional treatment). These examples are not inclusive of the vast number of terms that can be used in diagnosis of melanocytic lesions, 1, 14 and they are subject to further development and revision by consensus groups. The exact wording of the MPATH-Dx questionnaire is included in Appendix 1 (available at http://www.jaad.org).
Because we hypothesized that diagnostic difficulty would be concentrated in lesions with atypia, including ''thin'' low-risk melanomas, and because of the relative rarity of these lesions in routine practice, the distribution of cases in the sample sets intentionally included a higher proportion of cases in MPATH-Dx classes II to V (the so-called intermediate lesions and the low-stage melanomas) than typically encountered in practice: 10.4% (n = 25) class I, 15.0% (n = 36) class II, 25.0% (n = 60) class III, 24.2% (n = 58) class IV, and 25.4% (n = 61) class V. Participants were not informed of the distribution of biopsy cases.
CAPSULE SUMMARY
The 240 cases were divided into 5 different sets that each included the full range of MPATH-Dx classes. All pathologists interpreted 48 cases by using glass slides in phase I of the study; in phase II they interpreted a test set including 36 or 48 cases in either a glass or digital format. Data from the 50 pathologists assigned to the digital format reading during phase II were used in a separate study; therefore, only data from their phase I interpretations are included in this analysis.
Data collection
All participants completed a baseline survey assessing their demographic and clinical practice characteristics before being randomized to a test set. 8, 10 The slides were arranged in a random order for each participant. The patient's age, sex, and biopsy type and the anatomic location of the biopsy site were provided for each case. To limit the number of slides for the review and preclude any need for provision of additional sections (eg, levels through the block), pathologists were asked to assume that the glass slide was representative of the entire melanocytic lesion. To allow us to request a treatment recommendation for each lesion, they were also asked to assume that the margin was involved in all cases. Pathologists used their own microscopes and provided their diagnoses by using an online histology form that included the MPATH-Dx system to classify their diagnoses into 1 of the 5 MPATH-Dx classes.
After a washout period of at least 8 months, participants were invited to complete phase II, in which they viewed the same cases presented in a different randomly assigned order. Participants were not told that they were sent the same cases in phase II that they had already seen in phase I.
Analysis
We compared each pathologist's diagnosis with the consensus reference diagnosis for each case to estimate accuracy (rate of interobserver concordance). Overinterpretation was defined as the participant diagnosing a case at a higher MPATH-Dx class relative to the consensus reference diagnosis; underinterpretation was defined as the participant diagnosing a case at a lower MPATH-Dx class. Accurate diagnoses were those in agreement with the reference diagnosis. Confidence intervals accounted for both within-and across-participant variability by using variance estimates in the form {var(rate p ) 1 [ave(rate p ) 3 (1 À ave(rate p ))]/n c }/n p , where ave(rate p ) is the average rate among pathologists, var(rate p ) is the sample variance of rates among pathologists, n c is the number of cases interpreted by each pathologist, and n p is the number of pathologists. 15 We compared each pathologist's diagnosis for a single case in phase I with his or her diagnosis of the same case in phase II to estimate reproducibility (rate of intraobserver concordance). Reproducibility was defined as the proportion of interpretations of the same case that received the same MPATH-Dx class diagnosis by the same pathologist in both phase I and phase II. Confidence intervals were estimated by using a logit transformation and robust standard error that accounted for pathologist-level clustering.
The associations of pathologist characteristics with estimates of reproducibility and accuracy were assessed by comparing concordance rates between subgroups of pathologists (eg, subgroups based on pathologist level of experience or training). Logistic regression models were fit to determine the best combination of characteristics predicting accuracy and reproducibility and to assess their effects with adjustment for the effects of other related characteristics. Models used robust estimators of variance to account for correlation of case interpretations from the same pathologist. Stata statistical software (version 14, StataCorp LP, College Station, TX) was used.
RESULTS
Study population
Of 301 pathologists eligible for the study, 187 participants completed phase I interpretations and 118 completed glass slide interpretations during phase II (50 pathologists were randomized to interpret the cases in whole slide digital imaging format in phase II). The participating pathologists were predominantly male (61%), at least 50 years of Tool and Hierarchy for Diagnosis  OR: odds ratio J AM ACAD DERMATOL age (54%), and not affiliated with an academic medical center (72%), and most reported at least 10 years of experience interpreting melanocytic skin lesions (60%). To participate in the study, all pathologists were required to have interpreted melanocytic skin lesions in their clinical practice; 19% reported that more than a quarter of their caseloads included melanocytic lesions, and 40% were board-certified and/or fellowship-trained in dermatopathology. The majority of pathologists (86%) reported being moderately to extremely confident in their assessments of melanocytic lesions; however, more than half (69%) of the participants also reported that interpreting melanocytic skin lesions makes them more nervous than do other types of pathology.
Pathologist characteristics associated with accuracy Accuracy rates of phase I interpretations by pathologist characteristics are shown in Table I . No pathologist characteristics were significantly associated with rates of overinterpretation. Underinterpretation rates were lower among those pathologists who had academic affiliations, had a higher percentage of melanocytic skin lesions in their caseloads, had a higher volume of melanocytic skin lesions within a month's caseload, reported expertise in diagnosis of melanocytic lesions, and had board certification and/or fellowship training in dermatopathology.
Pathologist characteristics that remained significantly associated with accuracy in multivariable logistic regression models (Fig 1) Pathologist characteristics associated with reproducibility The reproducibility rates (indicating agreement of phase I and phase II interpretations of the same case) of the 118 pathologists who completed both phases of the study are shown in Table II . Rates were significantly higher among pathologists who had completed either a dermatopathology board certification and/or fellowship program, those with 10% or more of their caseload consisting of melanocytic lesions, and those who reported interpreting 60 or more melanocytic lesions per month. Fig 2 shows the multivariable model for reproducibility, with significantly higher reproducibility among board-certified and/or fellowship-trained pathologists and among those with more than 5 years interpreting melanocytic skin lesions. Caseload volume and composition no longer contributed to prediction of increased reproducibility when the effects of board certification/fellowship training and years of experience were accounted for.
DISCUSSION
In multivariable analysis, pathologists with board certification or fellowship training in dermatopathology and 5 or more years of experience had higher rates of reproducibility and accuracy. In addition, pathologists who had a higher caseload volume and interpreted more melanocytic lesions in practice demonstrated higher accuracy. Although the differences noted between groups reached statistical significance, the absolute quantitative differences were perhaps modest for some comparisons. Multivariable logistic regression model of accuracy as a function of pathologist characteristics (odds ratio estimates and 95% confidence intervals). Outcome of accuracy is defined as participant concordance with the reference diagnosis; odds ratio greater than 1 indicates increased concordance/accuracy. Pathologist-level factors considered for inclusion in the multivariable model of accuracy were dermatopathology board certification, fellowship training, years of experience interpreting melanocytic skin lesions (MSLs), affiliation with an academic medical center, practice size, melanocytic caseload composition (% MSLs), melanocytic caseload volume (MSL cases/mo), and self-perceived MSL expertise among peers.
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However, in view of the increasing number of skin biopsies performed each year, the impact of our findings at a population level needs to be considered. It is estimated that 23% of all skin biopsies performed among adults in the United States are of melanocytic lesions. 16 These findings are generally similar to those from other, less comprehensive studies. [16] [17] [18] [19] [20] [21] The consensus points to dermatopathologists being the best suited to interpret challenging melanocytic skin lesions. However, the influence of experience and higher case volume, which have been associated with better outcomes in other fields of medicine, 22 was not addressed in these studies, and these attributes have been found to be significant in this present study. Although the attributes are highly correlated, our data nevertheless suggest that clinical experience is an important attribute of accuracy, supporting the continuing involvement of ''legacy'' practitioners who have years of experience or have acquired diagnostic skills outside of a formal dermatopathology training program.
Our present and prior studies suggest directions for needed improvement in the field of diagnostic melanocytic pathology to better serve patients. The field could benefit substantially from efforts to simplify the diverse and confusing nomenclatures currently in existence. Our MPATH-Dx mapping tool, which is based on observer perceptions of risks of given lesions and the appropriate surgical interventions for them, is a reasonable first iteration to prompt the community of melanocytic lesion pathologists to move forward collectively to refine such a stratification schema incorporating general consensus viewpoints of the medical community. In addition, when new concepts and tools such as supplemental molecular tests to complement traditional histopathologic criteria are introduced, attempts should be promptly instituted to determine the evidence basis for those putative advancements, including determinations of their specificity, sensitivity, predictive value, and reproducibility.
Limitations and strengths of the study
Despite this being a large study, every study has limitations. The current data were gathered in a test situation, with only 1 slide per case and no opportunity for participating pathologists to consult with a colleague for second opinion, nor with the opportunity to request additional stains, deeper-level sections, or additional tests. For this reason, generalizability to real practice, where pathologists do have these opportunities, is not exact. Nevertheless, it is not uncommon in practice for the results of these Reproducibility outcome is the agreement of the participant phase II interpretation with his or her phase I interpretation of the same case. CI, Confidence interval. *P value for years interpreting melanocytic skin lesions of .47 is based on a trend test using a single 4-category ordinal variable in the context of a logistic regression model of misclassification, with clustering to account for within-and between-participant variability. A P value of .01 results from a test of 5 or more versus fewer than 5 years interpreting melanocytic skin lesions. This dichotomization is used in the multivariable model.
investigations to add little to the diagnostic specificity, and the participants were asked to assume that the single slide was representative. Additionally, although our findings are reported by classifying interpretations into the MPATH-Dx categories, this classification tool was not in clinical use at the time of our study. Finally, although the definition of accuracy is based on the consensus diagnosis among 3 experienced pathologists, which would be considered ideal in a clinical setting, the natural outcome of the cases is unknown. Given that the diagnostic truth is in the biology, our consensus reference diagnosis is the best (and yet imperfect, as it is subjective) proxy available to study accuracy.
The strengths of the current study include a large number of cases that although randomly selected to fill the full range of diagnostic classes from benign to invasive melanoma, were also weighted to include a higher proportion of the diagnostically more difficult ''intermediate'' lesions. We recruited a large and diverse population of pathologists to participate in this study and gathered a multitude of relevant variables on pathologist characteristics. Participating pathologists also had a broad range of levels of clinical experience.
CONCLUSION
Diagnoses of melanocytic tumors are more accurate among pathologists with specialty training and/ or more experience interpreting melanocytic lesions. These findings support the practice of referring difficult cases to more experienced pathologists to improve diagnostic accuracy, although the impact of these referrals on patient outcomes requires additional research. The Assessment form is divided into four secƟons: In SecƟon I you will render a primary diagnosis; in SecƟon II you will be allowed to indicate whether you were uncertain about this case and whether you feel it is intermediate between two diagnoses; you will select a clinical course for this case in SecƟon III and SecƟon IV comprises three follow-up quesƟons. Please try to spend the usual amount of Ɵme on each case as you would while diagnosing your own cases in pracƟce. Although this is an arƟficial exercise please give your best diagnosis. Assume the slide is representaƟve of the enƟre lesion and that the margins are posiƟve.
Ia. Histologic Assessment: Diagnoses (check the single best diagnosis)
No diagnosƟc alteraƟon No Yes, because it is our policy to get a second opinion on cases with this diagnosis. Yes, because I would want a second pathologist's opinion for diagnosƟc reasons (e.g. the diagnosis is challenging/borderline/uncertain).
LenƟgo related
LenƟgo simplex Solar lenƟgo Ephelis
Nevus and related
Common nevus
Footnotes:
** For Phase 2 data collecƟon, parƟcipants * © 2013, 2018 University of Washington. All rights reserved.
were required to enter a Breslow thickness between 0.01 and 25.00, otherwise they will be asked to revise their entry. *** For Phase 2 data collecƟon, if a parƟcipant enters in a mitoƟc figure count of 50 or greater they will receive the following pop-up message before they can conƟnue with their assessment.
